Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: Authorities are hoping large-scale manufacturers can use their low-cost supply chains and digital design expertise, including 3D printing, and repurpose some factories in order to make up the expected shortfall in vital medical hardware. Some of Britain's biggest aerospace and car companies have formed three teams to produce basic ventilators to help the country's National Health Service cope with the coronavirus outbreak. Meggitt Plc, which builds components including oxygen systems for civil aerospace and military fighter programs, is leading one consortium alongside engineers GKN, Thales SA and Renishaw Plc. The other two teams are being led by carmakers McLaren, which is looking at how to design a simple version of a ventilator, and Nissan Motor Co, which is working with others to support existing ventilator producers. Ventilators, machines which move air in and out of the lungs, could be the difference between life and death for coronavirus patients suffering breathing difficulties. But getting new production up to speed will not be easy, some in the manufacturing industry said. "Precision milling and 3D printing techniques could help manufacture complex parts," said Rene-Christopher Wollmann, program and platform director at Automobili Pininfarina, which uses virtual design software to build electric hypercars. "But this depends on how much know-how existing manufacturers (of ventilators) are prepared to share about the design of such a machine," he added. "Another bottleneck will be assembling such machines under conditions which are adequate for the medical industry." The idea of using automakers to supply medical equipment got started in China, where electric car maker BYD earlier this month began turning out 5 million face masks and 300,000 bottles of hand sanitizer a day. The Shenzhen-based automaker is backed by U.S. investor Warren Buffett. Since then the idea has spread to other industries and countries. European aerospace group Airbus is working across its processes to see if its 3D printing or production facilities can be of use. "The aim is for there to be a (ventilator) prototype in two weeks and for manufacturing to start in four weeks," one person familiar with the situation at the company said. In northern Italy, the epicenter of the virus outbreak outside China, Italian carmakers Ferrari and Fiat Chrysler Automobiles NV are in talks with the nation's biggest ventilator manufacturer to help it boost production, company officials said on Thursday. The Italian government has embarked on a big expansion of intensive care beds, many of which will require ventilators. A source familiar with the matter said sports car maker Ferrari NV would be ready to start manufacturing ventilator parts in its famous Maranello headquarters, close to a ventilator factory operated by small medical equipment maker Siare Engineering. The luxury carmaker had yet to make a final decision. "We're talking to Fiat Chrysler, with Ferrari and (component maker) Marelli to try to understand if they can lend us a hand in this process for the electronics part," Siare Engineering Chief Executive Gianluca Preziosa told Reuters. Siare could also benefit from the automakers' purchasing power, Preziosa said. A spokesman for Exor NV, parent firm of both Fiat Chrysler and Ferrari, said meetings had taken place on Thursday with Siare to study the feasibility of the idea and that a decision was expected shortly. The spokesman said two main options were being considered: help Siare to engineer a capacity increase at its plant with the support of technicians provided by Fiat Chrysler and Ferrari; or outsource production of ventilator parts to the carmakers' facilities. In the United States, the federal government is in talks with Detroit auto giants General Motors Co and Ford Motor Co about how they can help expand ventilator production, the companies and White House officials said on Wednesday. It would not be the first time Detroit retooled auto plants to confront a national crisis. During World War Two Ford, GM and the former Chrysler stopped building cars and directed their factories and engineers to mass-produce airplanes, tanks and other weaponry at unprecedented levels, earning Detroit the nickname the "Arsenal of Democracy." On Wednesday, U.S. President Donald Trump said he would invoke the Defense Production Act, a law dating back to the Korean War of the 1950s which grants the president broad authority to "expedite and expand the supply of resources from the U.S. industrial base," which could allow the government to speed production of masks, respirators, ventilators and other needed equipment. Ford CEO Jim Hackett told employees in a town hall meeting that Ford is working on building ventilators if the idea is feasible. GM CEO Mary Barra spoke to White House economic adviser Larry Kudlow about the issue after the company announced it would suspend North American production through March 30. Separately, Tesla CEO Elon Musk used his Twitter account to offer his company's services. "We will make ventilators if there is a shortage," Musk tweeted, responding to a suggestion that the billionaire repurpose a factory for the task. The comment immediately drew hundreds of replies urging him to act. Claim: World's governments draft manufacturers for virus treatment arsenal.

Answer: From Washington to London, Beijing to Rome, governments are drafting automakers and aerospace manufacturers to ramp up production of ventilators and other medical equipment to bolster what most experts say is an inadequate arsenal of coronavirus treatment tools.

Question: Paragraph: The 60-year-old sports fan, a surgeon who started and sold two pharmaceutical companies for a combined $8.6 billion, told Reuters in an interview this week that he wants to use Anschutz concert tours and sports events, and his NFL team's players, to encourage L.A. school children to adopt healthier lifestyles. "The NFL can do so much for this city," said Soon-Shiong in an interview at his west Los Angeles office. "Kids really rally around sports and entertainment and it could be a major catalyst to demonstrate what you can do in life by living better." Soon-Shiong grew up in South Africa, where he became a doctor in his early 20s and treated tuberculosis victims. After moving to the United States and becoming a surgeon at UCLA, he developed innovative methods to treat diabetes and cancer patients. The sale of his two companies for $8.6 billion made him the wealthiest person in Los Angeles, according to Forbes magazine, although he still is not a household name in the city. Under his plan, players would serve as mentors, encouraging students to eat better and exercise more. The most sophisticated methods used to deal with sports injuries could be shared with local doctors. "It's important to motivate students in middle and high school. That's when you can help reduce diabetes and obesity that cause illness," he said. "Maybe we can turn that illness to wellness." If he's successful in L.A., Soon-Shiong said he intends to make it a national program. Sources say the billionaire is assembling a group of other Los Angeles business and civic leaders to buy AEG. Soon-Shiong did not discuss details of his bid. Sources also said his buyer group includes private equity firm Guggenheim Partners, which this spring led a group that bought the Los Angeles Dodgers baseball team for $2 billion. AEG, which is owned by Denver billionaire Phil Anschutz, said on September 19 it had hired Blackstone Advisory Partners to sell the company. It is expected to fetch $6 billion to $8 billion, according to investment bankers with knowledge of its assets. Separately, Los Angeles for years has wanted to bring back a professional football team, and Soon-Shiong acknowledged that he has met with the NFL to lay out his plan to buy a team. AEG owns the Los Angeles Kings pro hockey franchise, the L.A. Galaxy soccer club and a 20 percent stake in the Los Angeles Lakers basketball team. It owns or operates sports and entertainment arenas worldwide, including the Staples Center in Los Angeles, and promotes concerts and other live action events. Soon-Shiong's family foundation has committed $1 billion to transform healthcare and intends to create a national health superhighway by which doctors can share biotech information and other data to improve diagnosis and care. His foundation gave $135 million to the Saint John's Health Center in Santa Monica and $100 million to reopen Martin Luther King Hospital, which serves lower income patients in south Los Angeles. A basketball fan who played in pickup games until tearing his Achilles tendon three years ago, Soon-Shiong owns a 5 percent stake in the Lakers, and he said he has become friends with superstar Kobe Bryant and other players, whom he sees as role models for young fans. In March, he and his actress wife, Michelle Chan, endowed the Chan Soon-Shiong Center for Sports Science at Saint John's, which will focus on sports medicine, physical therapy and stem cell research to help heal injuries. It works with sports medicine doctors, including the Kerlan-Jobe Orthopedic Clinic that treats the Kings, Lakers and L.A. Dodgers. Saint John's announced the sports science center at a dinner honoring AEG president Tim Leiweke in March, six months before Soon-Shiong showed his interest in the conglomerate. Claim: LA billionaire covets sports teams to promote health.

Answer: Bio-tech entrepreneur Patrick Soon-Shiong, the richest man in Los Angeles, intends to make a bid for sports and real estate firm Anschutz Entertainment Group and wants to bring a National Football League team back to the second most populous U.S. city.

Question: Paragraph: Gives a cost comparison with injected insulin. Given that the article stresses the need for injected insulin as an adjunct to inhaled insulin (in some cases), the cost would be higher. No quantitative data presented. No information on the efficacy of Exubera at controlling blood sugar as compared to existing methods of insulin delivery. No data on the side effects, or how many people who did not have pre-pre-existing lung disease experienced inflammation due to Exubera. No quantitative data presented. No long-term data on the side effects, or how many people who did not have pre-existing lung disease experienced inflammation due to Exubera. No data from any Exubera trials. No mention of study design or incidence of side effects. Provides American Diabetes Association statistics on prevalence. Does not appear to be disease mongering. Mentions that not all diabetics take insulin and some people with Type 2 can manage with oral hypoglycemics, diet and exercise. There is some discussion that more diabetics will take insulin if it is inhaled form, which may or may not be true. Balanced. FDA, American Diabetes Association, Juvenile Diabetes Foundation and diabetic patient perspective provided. No conflict of interest noted. (No mention if anyone received research funding from Pfizer.) Mention of alternative treatment (i.e. injections alone) and possible treatment needed in conjunction with inhalable insulin. There is mention of some of the side effects on the lungs (coughing or decrease in lung capacity) , and that the inhaled form of insulin is not appropriate for all diabetics, especially those with asthma or poorly controlled lung disease. There is a reminder that diabetics still need to check their blood sugar levels via needles, pens or pumps. Mentions availability of treatment and that Exubera won't replace injected insulin. The story focuses on recent FDA approval. No clear evidence that the story relied heavily on a press release; however, the financial information seems to be PR-driven. While investors may be interested that this could be a "$1 billion a year seller for Pfizer", people with diabetes who take daily insulin in this new form would appreciate quantitative information on the risks and benefits of Exubera. Claim: FDA approves first inhalable version of insulin

Answer:
This is a story about FDA approval for an inhaled form of insulin marketed as Exubera. The story discusses how this new form of insulin delivery may affect diabetics, possibly increasing adherence to blood sugar management by reducing the need for injected insulin. A cost comparison of the two forms of insulin is provided. There are appropriate caveats from medical professionals who specialize in diabetes care regarding the need for continued insulin injections for some diabetics. These warnings are contradictory to the story's sub-headline which states that Exubera is an "alternative to daily injections". (We realize that reporters don't write headlines, but someone at AP is responsible for it.) Some diabetics, especially those with Type 1 diabetes, may need a longer-acting injected insulin and cannot rely solely on inhaled insulin. The story discusses some potentially serious side effects, such as a decrease in lung capacity in some people, however, there is no data on the incidence of this or other side effects. Overall, there is little quantitative information on the efficacy of the new form of insulin compared with the existing method of insulin delivery. While investors may be interested that this could be a "$1 billion a year seller for Pfizer", diabetics who are considering inhaled insulin would appreciate quantitative information on the risks and benefits of Exubera.